Ribomic Inc

Ribomic maintains a strong liquidity position, with cash and equivalents amounting to ¥2.1 billion, representing 59.3% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, supported by a current ratio of 22.51, indicating minimal short-term liquidity risk. However, operating cash flow is negative at ¥-932.8 million, driven by ongoing R&D and preclinical development activities.

Profitability metrics are negative, with a net loss of ¥221.5 million and an operating loss of ¥326.8 million in the latest period. Return on equity (ROE) is -6.53%, and return on assets (ROA) is -6.24%, both significantly below the industry median for biotechnology firms. These results reflect the high R&D intensity typical of early-stage biotech companies.

The company operates as a single business segment, with no geographic revenue breakdown disclosed. This lack of diversification increases exposure to regulatory and market risks in its primary operating region. No material revenue concentration is reported, but the absence of geographic segmentation limits visibility into regional performance.

Growth trajectory is constrained by current financials, with no revenue reported and a net loss in the latest period. Outlook for the current fiscal year (FY) is neutral, with no significant revenue growth expected. The next FY is projected to remain in a development phase, with continued investment in clinical trials and platform development.

Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, the absence of disclosed dilution sources does not preclude future equity raises to fund operations.

Recent events include the continuation of preclinical and clinical programs, with no material regulatory or litigation developments reported in the latest filings. The company remains focused on advancing its pipeline of RNA-based therapeutics, with no significant changes in strategic direction.

The company maintains zero long-term debt, resulting in a debt-to-equity ratio well above the cohort median.

Cash conversion metrics are rated best-in-class at 4.21, far exceeding the cohort median of 0.87.

Operating losses improved by 8.9% year-over-year, indicating a slight stabilization in core operational performance.

Dilution and liquidity risks are assessed as low, suggesting manageable capital structure pressures for investors.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing funding.

Ribomic generated negative free cash flow of 1.05 billion JPY in the latest fiscal year.

Net income losses widened slightly year-over-year, with a negative 0.5% change in the latest period.